Total Funding
8
Total FundingPost-IPO Equity raised
Growth Score in past quarter
pts
Heat Score 8 in past quarter
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
1601948
ARCA biopharma develops genetically-targeted therapies for cardiovascular diseases.
Acquired by 
Oruka Therapeutics
- Patrick Wheeler: Chief Financial Officer
- Christopher D. Ozeroff: General Counsel, Secretary & Business Development Head
About the Company
ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.
ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular
pathophysiology, molecular genetics and clinical development.

